Persistent Asset Partners’s Lipocine LPCN Stock Holding History

Persistent Asset Partners’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,442	Closed	-$107K	–	871
2026 Q1	$107K	Sell	13,442 -57,134	-81%	-$498K	0.04%	234
2025 Q4	$567K	Buy	+70,576	New	+$237K	0.25%	114

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Persistent Asset Partners's LPCN Position: Q2 2026 in Review

Persistent Asset Partners sold out of Lipocine (LPCN) in Q2 2026, closing a stake of 13,442 shares — an estimated $107K sold.

Persistent Asset Partners first reported a position in LPCN in Q4 2025 and held it in 2 quarters. The position peaked at $567K in Q4 2025. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

Persistent Asset Partners reported no remaining Lipocine position as of Q2 2026 after selling out during the quarter.
Persistent Asset Partners sold 13,442 Lipocine shares in Q2 2026, an estimated $107K.
Persistent Asset Partners first reported a position in Lipocine in Q4 2025 and held it in 2 quarters.
Persistent Asset Partners's Lipocine position peaked at $567K in Q4 2025.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.